Jessica McBroom

March 18, 2022

Jessica McBroom is Director for International Economics and Competitiveness at the National Security Council, White House. Jessica has driven the President’s supply chain agenda since the beginning of the Biden-Harris Administration, including as the chief coordinator for the implementation of Executive Order 14017 on America’s Supply Chains. She is currently on detail from the Office of Industrial Policy at the Department of Defense. Prior to that, Jessica was in the private sector as Vice President at a major U.S. financial institution and also served as a Director at a major manufacturing-focused trade association. Jessica has also held positions at the Department of State. She has a B.A. from Tulane University in political science and a minor in the French language. She is originally from Detroit, Michigan

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

February 5, 2026

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent

Universities, Patents, and the Future of U.S. Competitiveness

December 15, 2025

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties

How Counterfeit Drugs Threaten U.S. Health and Innovation

November 19, 2025

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor